Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
:NVAX
NVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.01 - $13.34
Previous CloseN/A
Volume4.15M
Average Volume (3M)5.08M
Market Cap
$1.50B
Enterprise Value$721.89M
Total Cash (Recent Filing)$623.05M
Total Debt (Recent Filing)$228.49M
Price to Earnings (P/E)3.9
Beta1.62
Next Earnings
Nov 05, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.62
Shares Outstanding162,421,650
10 Day Avg. Volume4,276,457
30 Day Avg. Volume5,076,443
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue0.67
Enterprise Value/Gross Profit0.76
Enterprise Value/Ebitda1.46
Forecast
1Y Price Target
$11.00Price Target Upside23.60% Upside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical ResultsThe company has shown strong clinical results from its malaria vaccine and influenza vaccine programs, reinforcing the versatility of the platform.
Government ContractsThere is potential for NVAX to receive large government contracts, which could fund the development of its internal flu vaccines.
Vaccine DevelopmentThe approval of the 2025-2026 Nuvaxoid vaccine with a six-month refrigerated shelf-life makes the vaccine more attractive to distributors.
Bears Say
COVID-19 Vaccine MarketNovavax has reduced peak market share estimates for Nuvaxovid from 18% to 14% due to uncertainty in the COVID market.
Regulatory ChallengesThe higher burden of proof and cost for pivotal trials under the new FDA framework may raise the bar for signing new partnerships for Novavax's COVID-19/influenza combination (CIC) vaccine program.
Vaccine CommercializationThere is a difficult road ahead for Nuvaxovid, as commercialization efforts may take years to mature.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $5.01 and its highest was $13.34 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.50B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 05, 2025 which is in 27 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2025. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.008 by $0.612.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.49.
How many shares outstanding does Novavax have?
Novavax has 162,421,650 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of $0.62 in its last earnings report, beating expectations of $0.008. Following the earnings report the stock price went up 12.63%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$11.00 (23.60% Upside)
$11.00 (23.60% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 233.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.74%
12-Months-Change
Fundamentals
Return on Equity
30.06%
Trailing 12-Months
Asset Growth
-26.51%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a biotechnology company focused on the development and commercialization of innovative vaccines to prevent serious infectious diseases. The company primarily operates in the biopharmaceutical sector, with a strong emphasis on vaccine development using its proprietary nanoparticle technology platform. Novavax's core products include vaccines for respiratory syncytial virus (RSV), seasonal influenza, and COVID-19, as well as other infectious diseases.
NVAX Company Deck
NVAX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive achievements, including a significant milestone payment from the BLA approval in the U.S., successful cost reduction strategies, and promising data from the CIC and flu programs. However, these were somewhat offset by a notable decrease in total revenue compared to the previous year and the financial implications of a required post-marketing commitment study. Overall, the sentiment leans towards positive due to the outweighed highlights.View all NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$11.00
▲(23.60% Upside)
Technical Analysis
Anavex Life Sciences
―
CureVac
―
AbCellera Biologics
―
Pharvaris
―
Immunocore Holdings
―
Ownership Overview
0.39% Insiders
12.76% Mutual Funds
21.06% Other Institutional Investors
49.28% Public Companies and Individual Investors